SynCore Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 2.58%

SynCore Biotechnology Co Ltd (4192) has an Asset Resilience Ratio of 2.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 4192 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

NT$7.04 Million

≈ $221.67K USD Cash + Short-term Investments

Total Assets

NT$272.85 Million

≈ $8.60 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how SynCore Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is SynCore Biotechnology Co Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down SynCore Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of SynCore Biotechnology Co Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$7.04 Million	2.58%
Total Liquid Assets	NT$7.04 Million	2.58%

Asset Resilience Insights

Limited Liquidity: SynCore Biotechnology Co Ltd maintains only 2.58% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

SynCore Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare SynCore Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for SynCore Biotechnology Co Ltd (2015–2024)

The table below shows the annual Asset Resilience Ratio data for SynCore Biotechnology Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	2.19%	NT$6.96 Million ≈ $219.15K	NT$317.80 Million ≈ $10.01 Million	+0.43pp
2023-12-31	1.76%	NT$6.66 Million ≈ $209.83K	NT$378.36 Million ≈ $11.92 Million	+0.23pp
2022-12-31	1.53%	NT$6.66 Million ≈ $209.83K	NT$436.65 Million ≈ $13.76 Million	+0.72pp
2021-12-31	0.81%	NT$6.66 Million ≈ $209.83K	NT$824.44 Million ≈ $25.97 Million	+0.08pp
2020-12-31	0.73%	NT$6.66 Million ≈ $209.83K	NT$913.99 Million ≈ $28.80 Million	-0.14pp
2019-12-31	0.87%	NT$6.66 Million ≈ $209.83K	NT$763.88 Million ≈ $24.07 Million	+0.04pp
2018-12-31	0.83%	NT$6.66 Million ≈ $209.83K	NT$804.80 Million ≈ $25.36 Million	+0.04pp
2017-12-31	0.79%	NT$6.66 Million ≈ $209.83K	NT$845.89 Million ≈ $26.65 Million	+0.19pp
2016-12-31	0.60%	NT$6.66 Million ≈ $209.83K	NT$1.11 Billion ≈ $35.12 Million	-0.05pp
2015-12-31	0.65%	NT$6.63 Million ≈ $208.82K	NT$1.03 Billion ≈ $32.36 Million	--

pp = percentage points

About SynCore Biotechnology Co Ltd

TWO:4192 Taiwan Biotechnology

Market Cap

$22.77 Million

NT$722.64 Million TWD

Market Cap Rank

#24722 Global

#1549 in Taiwan

Share Price

NT$20.55

Change (1 day)

+0.24%

52-Week Range

NT$19.50 - NT$28.75

All Time High

NT$537.12